BREAKING
General Mills, Inc. (GIS) Misses Q3 EPS Estimates by 12.1% 12 minutes ago Red Cat (RCAT) Q4 Revenue Surges 315.8% to $26.2M, Tops Estimates Despite $0.17 Loss 45 minutes ago Envela (ELA) Q4 EPS of $0.23 Crushes Estimate by 156%, Revenue Surges 66.6% YoY to $80.5M 1 hour ago Heartflow (HTFL) Stock Surges 13% as Q4 Revenue of $49.1M Beats Estimates Despite $0.12 Loss 1 hour ago DLocal’s Strong 2025 Finish 1 hour ago Micron Technology’s Fiscal Q2 2026 Financial Review 1 hour ago Dogwood Therapeutics (DWTX) Q4 Loss Narrows to $0.26, Beats Estimates 17 hours ago General Mills (GIS) Q3 EPS Misses by 12% at $0.64 as Revenue Falls 8% YoY to $4.44B 17 hours ago Star Equity Holdings Slips to a Loss in Q4 FY25; Revenue Surges 69% to $56.8M 17 hours ago Ovid Therapeutics (OVID) Swings to $0.06 EPS in Q4 FY25 18 hours ago General Mills, Inc. (GIS) Misses Q3 EPS Estimates by 12.1% 12 minutes ago Red Cat (RCAT) Q4 Revenue Surges 315.8% to $26.2M, Tops Estimates Despite $0.17 Loss 45 minutes ago Envela (ELA) Q4 EPS of $0.23 Crushes Estimate by 156%, Revenue Surges 66.6% YoY to $80.5M 1 hour ago Heartflow (HTFL) Stock Surges 13% as Q4 Revenue of $49.1M Beats Estimates Despite $0.12 Loss 1 hour ago DLocal’s Strong 2025 Finish 1 hour ago Micron Technology’s Fiscal Q2 2026 Financial Review 1 hour ago Dogwood Therapeutics (DWTX) Q4 Loss Narrows to $0.26, Beats Estimates 17 hours ago General Mills (GIS) Q3 EPS Misses by 12% at $0.64 as Revenue Falls 8% YoY to $4.44B 17 hours ago Star Equity Holdings Slips to a Loss in Q4 FY25; Revenue Surges 69% to $56.8M 17 hours ago Ovid Therapeutics (OVID) Swings to $0.06 EPS in Q4 FY25 18 hours ago
ADVERTISEMENT
LLY

Eli Lilly and Company

$LLY NYSE Feb 26, 2026 All Day FY 2026

Investor Toolbox

Listen to Call

Recording not yet available.

Read Transcript

Transcript not yet available.

View Infographic

Infographic not yet available.

Earnings History

View past quarters and earnings trends.

View History

LLY Coverage

Event Eli Lilly and Company (LLY) Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes Mar 19, 2026 Event Eli Lilly and Company (LLY) Lilly’s EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis Mar 16, 2026 Transcript Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript Mar 10, 2026 Event Eli Lilly and Company (LLY) Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients Mar 5, 2026 News Eli Lilly and Company (LLY) Surges 5.1% — Developing Story Feb 23, 2026 News Eli Lilly and Company (LLY) to acquire Orna Therapeutics Feb 9, 2026 News Key highlights from Eli Lilly’s (LLY) Q4 2025 earnings results Feb 4, 2026 Transcript Eli Lilly and Company (LLY) Q2 2025 Earnings Call Transcript Jan 22, 2026